Roche’s obesity drug shows 15.5% weight loss in diabetes trial, challenging Eli Lilly, Novo Nordisk

Enicepatide also reduced HbA1c by 2.65 percentage points at the highest dose after 48 weeks, with Roche saying weight loss had not yet plateaued as it advances Phase 3 studies of the experimental treatment.